TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: decreased antisecretory drug use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: knee flexion angles at initial contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee flexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum vertical ground reaction force (VGRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone union rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute small bowel toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: team performance checklist scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of checklist items completed by residents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient loose stool
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in knee pain on standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peptic ulcer
Endpoint domain: Adverse events/effects
Primary endpoint: intracerebral hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: other hemorrhagic phenomena
Endpoint domain: Adverse events/effects
Primary endpoint: prostate cancer-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: sarcopenia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physical resilience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline physical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ATPs per 100 person-years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of shocks per 100 person-years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First occurrence of inappropriate shock per 100 patient-years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assistance with information needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Logistical coordination of cancer care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Recruitment of eligible patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum 25(OH)D(3) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to therapy in cutaneous hemangiomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferation of the subcutaneous component
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance in the live exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum AMH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute T2-LV change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent change in sUA from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Familial risk for chronic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of positive response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving HbA1c <7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of confirmed hypoglycemic events (HE)
Endpoint domain: Adverse events/effects
Primary endpoint: TSQM‐9 score for 'convenience'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mycologic recurrence rate (MRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: complete cure recurrence rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: oxygen pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Linear displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severity of conduct problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in levels of CU traits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstring extensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single hop for distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed 6-meter hop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crossover hop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triple hop for distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: engagement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Urinary albumin-to-creatinine ratio (uACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slow-flow/no-reflow phenomenon (SF-NR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac enzyme elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major adverse cardiac events at 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Mean drug concentration in RSOF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant displacement of DLTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Level of nasal nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hyperglycemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in insulin infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean differences in health state values
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of protein peaks associated with prostate cancer and BPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Undiscounted life-years gained
Endpoint domain: Mortality/survival
Primary endpoint: Discounted QALYs gained
Endpoint domain: Mortality/survival
Primary endpoint: T-cell alloimmunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: nocturnal hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients discontinuing study medication due to worsening heart failure
Endpoint domain: Adverse events/effects
Primary endpoint: Patient-oriented composite endpoint (PoCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Definite/probable stent thrombosis (ST)
Endpoint domain: Adverse events/effects
Primary endpoint: median nocturnal SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: meanQTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maxQTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of CD4+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Log-transformed concentrations of interleukin-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of fecal bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total prostate cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: Inappropriate PSA screening tests ordered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: meperidine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of low cardiac output syndrome (LCOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: dietary restraint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight and shape concern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year single-procedure success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluoroscopy times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operator fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day fatality rate
Endpoint domain: Mortality/survival
Primary endpoint: Increase in MVPA after school
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in MVPA on Saturdays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gain in the best ON time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration over time curve of levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COMT inhibition by entacapone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to normal daily activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Temperature of vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CBH
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of scabies
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of pediculosis corporis
Endpoint domain: Adverse events/effects
Primary endpoint: T3 body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alanine aminotransferase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: aspartate transaminase (AST) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: participant-reported improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arm pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean best spectacle‐corrected visual acuity (BSCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictability +/‐1.00 D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean clinical attachment level (CAL) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-density lipoprotein cholesterol (LDL-C) levels <2.59 mmol/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum oxygen consumption (Max VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lean body weight (LBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of pulmonary embolism
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of deep venous thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: proportion of patients with hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: zBMI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of disordered respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection of apnea or hypoventilation by pulse oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence and intensity of injection pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological benefit (HIV RNA load <400 copies/mL at week 24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: free floating anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: phobic anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin conductance response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy related to HIV testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of retching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional status (weight Z-score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived effectiveness of HPV vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Support for vaccine mandate policy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: odor reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ostomy adjustment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean GAF score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of rehospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Sun safety knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sun safety behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean CD4 cell count changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival at day 28
Endpoint domain: Mortality/survival
Primary endpoint: Center of Pressure area (COP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anteroposterior range of COP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medial-lateral standard deviation of COP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distance error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of subsequent CT acquisitions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: diagnostic yield of ILR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asystolic response in tilt table testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change from baseline FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Investigator's global asthma evaluation score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parent/guardian global asthma evaluation score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of a first visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SSEs over 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FSFI desire domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FSDS-R-13 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement of neurologic, functional and cognitive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vasomotor factor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operating time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: tissue trauma markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ANP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease-Free Survival (DFS) at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative Cognitive Dysfunction (POCD) at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Cognitive Dysfunction (POCD) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: testosterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in nightmares
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Genotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of questions asked by patients
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of issues discussed by patients
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Unmet information needs about the future
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quality of family relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: physical well‐being
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postprandial muscle protein synthesis (MPS) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of aneurysm repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood manganese concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PCR-corrected clinical failure at day 90
Endpoint domain: Mortality/survival
Primary endpoint: Number of hypokinetic segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Single-beat elastance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pressure-volume area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physical self-concept scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: total oxycodone dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS scores upon entry into the PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of sensorimotor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for repeat block procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 25OHD levels >75 nmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hit rate to go stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activation during no-go trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: behavioral performance on cued trials
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Difference in SBP between ES-H55 device and auscultatory method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in DBP between ES-H55 device and auscultatory method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Requirement for further hip surgery
Endpoint domain: Mortality/survival
Primary endpoint: Tiredness on the intervention day
Endpoint domain: Adverse events/effects
Primary endpoint: Local tenderness
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of vancomycin therapy
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Overall hospital use of intravenous vancomycin
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Apical seal leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change talk 'towards change' at follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recovery from halitosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLMS index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLMW index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of leg discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall risk of immediate postoperative sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of blood glucose measurements in target range (80‐140 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median blood glucose after transition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes